News

Phase I Clinical Trial at the University of Liverpool



The Phase I Clinical Trial to test AKL’s lead anti-inflammatory clinical candidate, APPA, as a potential new treatment for osteoarthritis is underway at the University of Liverpool Clinical Trials Unit. The trial has been approved for NIHR support. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people, and is the leading cause of joint pain and stiffness in older people. Improved func...
Read More

MHRA Approval for Formal Human Trials to Start



The University of Liverpool, as Sponsor of APPA's clinical program, has received clinical trial authorisation (CTA) from the MHRA (Medicines & Healthcare Products Regulatory Agency) to commence the Phase I clinical trial. The ongoing clinical program will test AKLRD’s lead candidate, APPA, as a potential new treatment for osteoarthritis. David Sharples, Chief Executive Officer at ALKRD Ltd, said "This is a huge achievement for AKLRD and ...
Read More

Under-exploited plants offer untold economic promise



A recent article in Nature by Ameenah Gurib Fakim, President of Mauritius and former Professor of Organic Chemistry, about the abundance of commercially available drugs that have their origins in plants. "Artemisinin, ginkgolides, quinine, reserpine, scopolamine, paclitaxel. What do these molecules have in common? They are all extracted from plants and transformed into useful drugs, treating conditions including malaria, nausea, cancer and hig...
Read More

AKLRD and APPA in the Press



Recently there have been various press reports on AKLRD's collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively.     Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development Technology: Liverpool and AKLRD collaborate to evaluate APPA...
Read More

Liverpool University Press Release



Clinical trial for new innovative Osteoarthritis drug The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people*, and is the leading cause of joint pain and stiffness in older people. As part of their research and dev...
Read More

Summary of Effects of APPA on Neutrophils



AKLRD, in collaboration with the University of Liverpool, were accepted for a presentation at the 2016 OARSI (Osteoarthritis Research Society International) Congress Summary of Effects of APPA on Human Neutrophils Function APPA is a synergistic combination of 2 synthetic anti-inflammatory molecules. APPA has shown efficacy in several animal models of osteoarthritis, decreasing pain and meniscal cartilage damage. Its efficacy is thought to ...
Read More

APPA has completed required preclinical studies



We believe APPA is now ready to apply for regulatory approval to start formal human trials now that required preclinical toxicology studies have been completed. There is a considerable body of evidence behind the efficacy, safety, tolerability and mode of action of APPA. Consistent with data in the public domain, the studies undertaken indicate that the toxicity potential of orally administered APPA is low. In vitro genotoxicity panel with ...
Read More

New Family Link to Osteoarthritis



Brothers and sisters of osteoarthritis patients are twice as likely to develop the condition themselves, according to researchers in the East Midlands. The study, carried out at Nottingham’s City Hospital, also discovered that men were more likely to inherit the disease than women. Osteoarthritis is a painful condition causing inflammation and loss of cartilage, most commonly in the knee. Almost 500 patients with osteoarthritis took part in the...
Read More
Page 1 of 212